{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:05:32Z","timestamp":1789412732576,"version":"build-2803163510"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"DOI":"10.1007\/s42000-026-00819-7","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:36:27Z","timestamp":1789410987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An illustrative summary of receptor-mediated mechanisms involved in the therapeutic regulation of type 2 diabetes"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7619-1546","authenticated-orcid":false,"given":"Kawalpreet","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8789-9378","authenticated-orcid":false,"given":"Gurdeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"819_CR1","doi-asserted-by":"publisher","unstructured":"Leahy JL (2005) Pathogenesis of type 2 diabetes mellitus. Arch Med Res 36(3):197\u2013209. https:\/\/doi.org\/10.1016\/j.arcmed.2005.01.003","DOI":"10.1016\/j.arcmed.2005.01.003"},{"key":"819_CR2","unstructured":"World Health Organization Diabetes. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes Accessed 19 December 2025"},{"issue":"10365","key":"819_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R et al (2022) Type 2 diabetes. Lancet 400(10365):1803\u20131820","journal-title":"Lancet"},{"key":"819_CR4","doi-asserted-by":"publisher","unstructured":"Chong K, Chang JK, Chuang LM (2024) Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies. Kaohsiung J Med Sci 40(3):212\u2009\u2013\u200920. https:\/\/doi.org\/10.1002\/kjm2.12800","DOI":"10.1002\/kjm2.12800"},{"key":"819_CR5","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2165\/00003495-200464120-00006","volume":"64","author":"M Rendell","year":"2004","unstructured":"Rendell M (2004) The role of sulphonylureas in the management of type 2 diabete mellitus. Drugs 64:1339\u20131358. https:\/\/doi.org\/10.2165\/00003495-200464120-00006","journal-title":"Drugs"},{"issue":"5","key":"819_CR6","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1042\/BST20150096","volume":"43","author":"H de Wet","year":"2015","unstructured":"de Wet H, Proks P (2015) Correction: Molecular action of sulphonylureas on KATP channels: a real partnership between drugs and nucleotides. Biochem Soc Trans 43(5):901\u2013907. https:\/\/doi.org\/10.1042\/BST20150096","journal-title":"Biochem Soc Trans"},{"key":"819_CR7","doi-asserted-by":"publisher","unstructured":"Nauck MA, Quast DR, Wefers J et al (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes\u2013state-of-the-art. Mol Metab 46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","DOI":"10.1016\/j.molmet.2020.101102"},{"issue":"4","key":"819_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.apsb.2012.06.003","volume":"2","author":"J Yin","year":"2012","unstructured":"Yin J, Ye J, Jia W (2012) Effects and mechanisms of berberine in diabetes treatment. Acta Pharm Sin B 2(4):327\u2013334. https:\/\/doi.org\/10.1016\/j.apsb.2012.06.003","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"819_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1210\/er.2017-00073","volume":"38","author":"A Belfiore","year":"2017","unstructured":"Belfiore A, Malaguarnera R, Vella V et al (2017) Insulin receptor isoforms in physiology and disease: an updated view. Endocr Rev 38(5):379\u2013431 PMID: 28973479","journal-title":"Endocr Rev"},{"issue":"1","key":"819_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/medicina58010109","volume":"58","author":"AM Patti","year":"2022","unstructured":"Patti AM, Giglio RV, Papanas N et al (2022) Experimental and emerging free fatty acid receptor agonists for the treatment of type 2 diabetes. Medicina 58(1):109. https:\/\/doi.org\/10.3390\/medicina58010109","journal-title":"Medicina"},{"issue":"6","key":"819_CR11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1210\/er.20080047","volume":"30","author":"A Belfiore","year":"2009","unstructured":"Belfiore A, Frasca F, Pandini G et al (2009) Insulin receptor isoforms and insulin receptor\/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30(6):586\u2013623. https:\/\/doi.org\/10.1210\/er.20080047","journal-title":"Endocr Rev"},{"issue":"5","key":"819_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/dmrr.225","volume":"17","author":"G Sesti","year":"2001","unstructured":"Sesti G, Federici M, Lauro D et al (2001) Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. DMRR 17(5):363\u2013373. https:\/\/doi.org\/10.1002\/dmrr.225","journal-title":"DMRR"},{"key":"819_CR13","doi-asserted-by":"publisher","unstructured":"Youngren JF (2007) Regulation of insulin receptor function. Cell Mol Life Sci 64(7):873\u2009\u2013\u200991. https:\/\/doi.org\/10.1007\/s00018-007-6359-9","DOI":"10.1007\/s00018-007-6359-9"},{"key":"819_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1023\/A:1006823109415","volume":"182","author":"J Avruch","year":"1998","unstructured":"Avruch J (1998) Insulin signal transduction through protein kinase cascades. Mol Cell Biochem 182:31\u201348. https:\/\/doi.org\/10.1023\/A:1006823109415","journal-title":"Mol Cell Biochem"},{"key":"819_CR15","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/s12276-023-01101-1","volume":"55","author":"NO Yunn","year":"2023","unstructured":"Yunn NO, Kim J, Ryu SH et al (2023) A stepwise activation model for the insulin receptor. Exp Mol Med 55:2147\u20132161. https:\/\/doi.org\/10.1038\/s12276-023-01101-1","journal-title":"Exp Mol Med"},{"issue":"1","key":"819_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/ijms25010108","volume":"25","author":"G Biondi","year":"2023","unstructured":"Biondi G, Marrano N, Borrelli A et al (2023) The p66Shc redox protein and the emerging complications of diabetes. Int J Mol Sci 25(1):108. https:\/\/doi.org\/10.3390\/ijms25010108","journal-title":"Int J Mol Sci"},{"key":"819_CR17","doi-asserted-by":"publisher","unstructured":"Mousavi S, Khazeei Tabari MA, Bagheri A et al (2022) The role of p66Shc in diabetes: a comprehensive review from bench to bedside. J Diabetes Res 2022(7703520). https:\/\/doi.org\/10.1155\/2022\/7703520","DOI":"10.1155\/2022\/7703520"},{"issue":"30","key":"819_CR18","doi-asserted-by":"publisher","first-page":"13420","DOI":"10.1073\/pnas.1008647107","volume":"107","author":"SC Ranieri","year":"2010","unstructured":"Ranieri SC, Fusco S, Panieri E et al (2010) Mammalian life-span determinant p66shcA mediates obesity-induced insulin resistance. Proc Natl Acad Sci U S A 107(30):13420\u201313425. https:\/\/doi.org\/10.1073\/pnas.1008647107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"819_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1474-9726.2010.00641.x","volume":"10","author":"AA Tomilov","year":"2011","unstructured":"Tomilov AA, Ramsey JJ, Hagopian K et al (2011) The Shc locus regulates insulin signaling and adiposity in mammals. Aging Cell 10(1):55\u201365. https:\/\/doi.org\/10.1111\/j.1474-9726.2010.00641.x","journal-title":"Aging Cell"},{"key":"819_CR20","doi-asserted-by":"publisher","first-page":"110823","DOI":"10.1016\/j.biopha.2020.110823","volume":"132","author":"C Hui","year":"2020","unstructured":"Hui C, Tomilov A, Garcia C et al (2020) Novel idebenone analogs block Shc\u2019s access to insulin receptor to improve insulin sensitivity. Biomed Pharmacother 132:110823. https:\/\/doi.org\/10.1016\/j.biopha.2020.110823","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"819_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.4239\/wjd.v5.i4.511","volume":"5","author":"L Rui","year":"2014","unstructured":"Rui L (2014) SH2B1 regulation of energy balance, body weight, and glucose metabolism. World J Diabetes 5(4):511\u2013526. https:\/\/doi.org\/10.4239\/wjd.v5.i4.511","journal-title":"World J Diabetes"},{"issue":"9","key":"819_CR22","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.2337\/db08-1388","volume":"58","author":"DL Morris","year":"2009","unstructured":"Morris DL, Cho KW, Zhou Y et al (2009) SH2B1 enhances insulin sensitivity by both stimulating the insulin receptor and inhibiting tyrosine dephosphorylation of insulin receptor substrate proteins. Diabetes 58(9):2039\u20132047. https:\/\/doi.org\/10.2337\/db08-1388","journal-title":"Diabetes"},{"issue":"3","key":"819_CR23","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/dom.12019","volume":"15","author":"V Bhaskar","year":"2013","unstructured":"Bhaskar V, Lau A, Goldfine ID et al (2013) XMetA, an allosteric monoclonal antibody to the insulin receptor, improves glycaemic control in mice with diet-induced obesity. Diabetes Obes Metab 15(3):272\u2013275. https:\/\/doi.org\/10.1111\/dom.12019","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"819_CR24","doi-asserted-by":"publisher","first-page":"P466","DOI":"10.1124\/jpet.115.229690","volume":"356","author":"P Bezwada","year":"2016","unstructured":"Bezwada P, Zhao J, Der K et al (2016) A Novel Allosteric Insulin Receptor\u2013Activating Antibody Reduces Hyperglycemia without Hypoglycemia in Diabetic Cynomolgus Monkeys. J Pharmacol Exp Ther 356(2):P466\u2013P473. https:\/\/doi.org\/10.1124\/jpet.115.229690","journal-title":"J Pharmacol Exp Ther"},{"key":"819_CR25","doi-asserted-by":"publisher","unstructured":"Moller DE (2000) Potential role of TNF-\u03b1 in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 11(6):212-7. https:\/\/doi.org\/10.1016\/S1043-2760(00)00272-1","DOI":"10.1016\/S1043-2760(00)00272-1"},{"issue":"35","key":"819_CR26","doi-asserted-by":"publisher","first-page":"26055","DOI":"10.1016\/S0021-9258(19)74276-8","volume":"268","author":"R Feinstein","year":"1993","unstructured":"Feinstein R, Kanety H, Papa MZ et al (1993) Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268(35):26055\u201326058. https:\/\/doi.org\/10.1016\/S0021-9258(19)74276-8","journal-title":"J Biol Chem"},{"issue":"17","key":"819_CR27","doi-asserted-by":"publisher","first-page":"e2401716121","DOI":"10.1073\/pnas.2401716121","volume":"121","author":"JR Woo","year":"2024","unstructured":"Woo JR, Bae SH, Wales TE et al (2024) The serine phosphorylations in the IRS-1 PIR domain abrogate IRS-1 and IR interaction. Proc Natl Acad Sci U S A 121(17):e2401716121. https:\/\/doi.org\/10.1073\/pnas.2401716121","journal-title":"Proc Natl Acad Sci U S A"},{"key":"819_CR28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.imlet.2017.04.003","volume":"186","author":"YL Chen","year":"2017","unstructured":"Chen YL, Qiao YC, Xu Y et al (2017) Serum TNF-\u03b1 concentrations in type 2 diabetes mellitus patients and diabetic nephropathy patients: A systematic review and meta-analysis. Immunol Lett 186:52\u201358. https:\/\/doi.org\/10.1016\/j.imlet.2017.04.003","journal-title":"Immunol Lett"},{"key":"819_CR29","doi-asserted-by":"publisher","unstructured":"Nanjan MJ, Mohammed M, Kumar BP et al (2018) Thiazolidinediones as antidiabetic agents: A critical review. Bioorg Chem 77:548\u2009\u2013\u200967. https:\/\/doi.org\/10.1016\/j.bioorg.2018.02.009","DOI":"10.1016\/j.bioorg.2018.02.009"},{"issue":"3","key":"819_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.bbrc.2010.05.153","volume":"397","author":"C Chen","year":"2010","unstructured":"Chen C, Zhang Y, Huang C (2010) Berberine inhibits PTP1B activity and mimics insulin action. Biochem Biophys Res Commun 397(3):543\u2013547. https:\/\/doi.org\/10.1016\/j.bbrc.2010.05.153","journal-title":"Biochem Biophys Res Commun"},{"issue":"15","key":"819_CR31","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1016\/j.bmc.2007.05.027","volume":"15","author":"R Maccari","year":"2007","unstructured":"Maccari R, Paoli P, Ottan\u00e0 R et al (2007) 5-Arylidene-2, 4-thiazolidinediones as inhibitors of protein tyrosine phosphatases. Bioorg Med Chem 15(15):5137\u20135149. https:\/\/doi.org\/10.1016\/j.bmc.2007.05.027","journal-title":"Bioorg Med Chem"},{"key":"819_CR32","doi-asserted-by":"publisher","unstructured":"Konidala SK, Kotra V, Danduga RC, Kola PK (2020) Coumarin-chalcone hybrids targeting insulin receptor: Design, synthesis, anti-diabetic activity, and molecular docking. Bioorg Chem 104. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104207","DOI":"10.1016\/j.bioorg.2020.104207"},{"issue":"14","key":"819_CR33","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.3390\/ijms23147793","volume":"23","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu X, Bi X, Huang J, Zhou L (2022) The insulin receptor: an important target for the development of novel medicines and pesticides. Int J Mol Sci 23(14):7793. https:\/\/doi.org\/10.3390\/ijms23147793","journal-title":"Int J Mol Sci"},{"key":"819_CR34","doi-asserted-by":"publisher","unstructured":"Lan ZJ, Lei Z, Yiannikouris A, Yerramreddy TR et al (2020) Non-peptidyl small molecule, adenosine, 5\u2032-Se-methyl-5\u2032-seleno-, 2\u2032, 3\u2032-diacetate, activates insulin receptor and attenuates hyperglycemia in type 2 diabetic Lepr db\/db mice. Cell Mol Life Sci 77:1623-43. https:\/\/doi.org\/10.1007\/s00018-019-03249-4","DOI":"10.1007\/s00018-019-03249-4"},{"issue":"23","key":"819_CR35","doi-asserted-by":"publisher","first-page":"1800709","DOI":"10.1002\/mnfr.201800709","volume":"62","author":"J Chen","year":"2008","unstructured":"Chen J, Sun J, Prinz RA et al (2008) Gingerenone A sensitizes the insulin receptor and increases glucose uptake by inhibiting the activity of p70 S6 kinase. Mol Nutr Food Res 62(23):1800709. https:\/\/doi.org\/10.1002\/mnfr.201800709","journal-title":"Mol Nutr Food Res"},{"key":"819_CR36","doi-asserted-by":"publisher","unstructured":"Qiang G, Xue S, Yang JJ et al (2014) Identification of a small molecular insulin receptor agonist with potent antidiabetes activity. Diabetes 63(4):1394\u2009\u2013\u2009409. https:\/\/doi.org\/10.2337\/db13-0334","DOI":"10.2337\/db13-0334"},{"key":"819_CR37","doi-asserted-by":"publisher","unstructured":"Diesel B, Kulhanek-Heinze S, H\u00f6ltje M et al (2007) \u03b1-Lipoic acid as a directly binding activator of the insulin receptor: protection from hepatocyte apoptosis. Biochem 46(8):2146-55. https:\/\/doi.org\/10.1021\/bi602547m","DOI":"10.1021\/bi602547m"},{"key":"819_CR38","doi-asserted-by":"publisher","unstructured":"Panigrahi A, MohantyS (2023) Efficacy and safety of HIMABERB\u00ae Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. BMC endocr disord23(1):190 https:\/\/doi.org\/10.1186\/s12902-023-01442-y","DOI":"10.1186\/s12902-023-01442-y"},{"key":"819_CR39","doi-asserted-by":"publisher","unstructured":"Seino S, Zhang CL, Shibasaki T (2010) Sulfonylurea action re-revisited. J Diabetes Investig 1(1\u20102):37\u2009\u2013\u20099. https:\/\/doi.org\/10.1111\/j.20401124.2010.00014.x","DOI":"10.1111\/j.20401124.2010.00014.x"},{"issue":"12","key":"819_CR40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1055\/s-2007-1003387","volume":"24","author":"U Panten","year":"1992","unstructured":"Panten U, Schwanstecher M, Schwanstecher C (1992) Pancreatic and extrapancreatic sulfonylurea receptors. Horm Metab Res 24(12):549\u2013554. https:\/\/doi.org\/10.1055\/s-2007-1003387","journal-title":"Horm Metab Res"},{"key":"819_CR41","doi-asserted-by":"publisher","unstructured":"Burke MA, Mutharasan RK, Ardehali H (2008) The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel. Circ Res 102(2):164\u2009\u2013\u200976. https:\/\/doi.org\/10.1161\/CIRCRESAHA.107.165324","DOI":"10.1161\/CIRCRESAHA.107.165324"},{"issue":"1","key":"819_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.yjmcc.2004.11.024","volume":"39","author":"NQ Shi","year":"2005","unstructured":"Shi NQ, Ye B, Makielski JC (2005) Function and distribution of the SUR isoforms and splice variants. J Mol Cell Cardiol 39(1):51\u201360. https:\/\/doi.org\/10.1016\/j.yjmcc.2004.11.024","journal-title":"J Mol Cell Cardiol"},{"key":"819_CR43","doi-asserted-by":"publisher","unstructured":"Wu JX, Ding D, Wang M et al (2018) Ligand binding and conformational changes of SUR1 subunit in pancreatic ATP-sensitive potassium channels. Protein Cell 9(6):553\u2009\u2013\u200967. https:\/\/doi.org\/10.1007\/s13238-018-0530-y","DOI":"10.1007\/s13238-018-0530-y"},{"issue":"29","key":"819_CR44","doi-asserted-by":"publisher","first-page":"6198","DOI":"10.1021\/acs.jpcb.0c02720","volume":"124","author":"K Walczewska-Szewc","year":"2020","unstructured":"Walczewska-Szewc K, Nowak W (2020) Structural determinants of insulin release: disordered N-terminal tail of Kir6. 2 affects potassium channel dynamics through interactions with sulfonylurea binding region in a SUR1 partner. J Phys Chem 124(29):6198\u20136211. https:\/\/doi.org\/10.1021\/acs.jpcb.0c02720","journal-title":"J Phys Chem"},{"key":"819_CR45","doi-asserted-by":"publisher","unstructured":"Del Prato S, Pulizzi N (2006) The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metab 55(S20\u2013S27). https:\/\/doi.org\/10.1016\/j.metabol.2006.02.003","DOI":"10.1016\/j.metabol.2006.02.003"},{"key":"819_CR46","doi-asserted-by":"publisher","unstructured":"Riddle M (2000) Combining sulfonylureas and other oral agents. Am J Med 108(6):15\u201322. https:\/\/doi.org\/10.1016\/S0002-9343(00)00338-7","DOI":"10.1016\/S0002-9343(00)00338-7"},{"key":"819_CR47","doi-asserted-by":"publisher","unstructured":"Tomlinson B, Patil NG, Fok M et al (2022) The role of sulfonylureas in the treatment of type 2 diabetes. Expert Opin Pharmacother 23(3):387\u2013403. https:\/\/doi.org\/10.1080\/14656566.2021.1999413","DOI":"10.1080\/14656566.2021.1999413"},{"key":"819_CR48","doi-asserted-by":"publisher","unstructured":"Shrestha D, Dhingra A, Shakya S et al (2025) From Glucose Control to Multifaceted Benefits: The Rise of Modern Sulphonylureas in Diabetes Care. Curr Diab Rep 25(28). https:\/\/doi.org\/10.1007\/s11892-025-01582-6","DOI":"10.1007\/s11892-025-01582-6"},{"issue":"1","key":"819_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2174\/1568026620666191224141617","volume":"20","author":"W Lv","year":"2020","unstructured":"Lv W, Wang X, Xu Q et al (2020) Mechanisms and characteristics of sulfonylureas and glinides. Curr Top Med Chem 20(1):37\u201356. https:\/\/doi.org\/10.2174\/1568026620666191224141617","journal-title":"Curr Top Med Chem"},{"key":"819_CR50","doi-asserted-by":"publisher","unstructured":"Seino S, Zhang CL, Shibasaki T (2010) Sulfonylurea action re-revisited. J Diabetes Investig 1(1\u20102):37\u2009\u2013\u20099. https:\/\/doi.org\/10.1111\/j.2040-1124.2010.00014.x","DOI":"10.1111\/j.2040-1124.2010.00014.x"},{"issue":"3","key":"819_CR51","doi-asserted-by":"publisher","first-page":"149","DOI":"10.5483\/BMBRep.2021.54.3.233","volume":"54","author":"K Lee","year":"2021","unstructured":"Lee K (2021) Epac: new emerging cAMP-binding protein. BMB Rep 54(3):149\u2013156. https:\/\/doi.org\/10.5483\/BMBRep.2021.54.3.233","journal-title":"BMB Rep"},{"issue":"10","key":"819_CR52","doi-asserted-by":"publisher","first-page":"P8279","DOI":"10.1074\/jbc.m211682200","volume":"278","author":"G Kang","year":"2003","unstructured":"Kang G, Joseph JW, Chepurny OG et al (2003) Epac-selective cAMP analog 8-pCPT-2\u2032-O-Me-cAMP as a stimulus for Ca2+-induced Ca2\u2009+\u2009release and exocytosis in pancreatic \u03b2-cells. J Biol Chem 278(10):P8279\u2013P8285. https:\/\/doi.org\/10.1074\/jbc.m211682200","journal-title":"J Biol Chem"},{"issue":"13","key":"819_CR53","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1002\/cbic.200800216","volume":"9","author":"MJ Vliem","year":"2008","unstructured":"Vliem MJ, Ponsioen B, Schwede F et al (2008) 8-pCPT-2\u2019-O-Me-cAMP-AM: an improved Epac-selective cAMP analogue. ChemBioChem 9(13):2052\u20132054. https:\/\/doi.org\/10.1002\/cbic.200800216","journal-title":"ChemBioChem"},{"issue":"1","key":"819_CR54","doi-asserted-by":"publisher","first-page":"P191","DOI":"10.1124\/mol.112.081943","volume":"83","author":"RE Jarrard","year":"2013","unstructured":"Jarrard RE, Wang Y, Salyer AE et al (2013) Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2\u2009+\u2009influx. Mol Pharmacol 83(1):P191\u2013205. https:\/\/doi.org\/10.1124\/mol.112.081943","journal-title":"Mol Pharmacol"},{"issue":"5","key":"819_CR55","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1042\/BST20190254","volume":"47","author":"U Luchowska-Sta\u0144ska","year":"2019","unstructured":"Luchowska-Sta\u0144ska U, Morgan D, Yarwood SJ et al (2019) Selective small-molecule EPAC activators. Biochem Soc Trans 47(5):1415\u20131427. https:\/\/doi.org\/10.1042\/BST20190254","journal-title":"Biochem Soc Trans"},{"issue":"13","key":"819_CR56","doi-asserted-by":"publisher","first-page":"11303","DOI":"10.1074\/jbc.M211495200","volume":"278","author":"Briscoe","year":"2003","unstructured":"Briscoe CP, Tadayyon M, Andrews JL et al (2003) The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 278(13):11303\u201311311. https:\/\/doi.org\/10.1074\/jbc.M211495200","journal-title":"J Biol Chem"},{"issue":"13","key":"819_CR57","doi-asserted-by":"publisher","first-page":"11312","DOI":"10.1074\/jbc.M211609200","volume":"278","author":"AJ Brown","year":"2003","unstructured":"Brown AJ, Goldsworthy SM, Barnes AA et al (2003) The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 278(13):11312\u201311319. https:\/\/doi.org\/10.1074\/jbc.M211609200","journal-title":"J Biol Chem"},{"issue":"9","key":"819_CR58","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.2337\/db08-0307","volume":"57","author":"S Edfalk","year":"2008","unstructured":"Edfalk S, Steneberg P, Edlund H (2008) Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57(9):2280\u20132287. https:\/\/doi.org\/10.2337\/db08-0307","journal-title":"Diabetes"},{"key":"819_CR59","doi-asserted-by":"publisher","unstructured":"Li Z, Xu X, Huang W, Qian H (2018) Free fatty acid receptor 1 (FFAR1) as an emerging therapeutic target for type 2 diabetes mellitus: recent progress and prevailing challenges. Med Res Rev 38(2):381\u2013425. https:\/\/doi.org\/10.1002\/med.21441","DOI":"10.1002\/med.21441"},{"issue":"1","key":"819_CR60","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev-physiol-032122-030352","volume":"85","author":"D Samovski","year":"2023","unstructured":"Samovski D, Jacome-Sosa M, Abumrad NA (2023) Fatty acid transport and signaling: mechanisms and physiological implications. Annu Rev Physiol 85(1):317\u2013337","journal-title":"Annu Rev Physiol"},{"issue":"6","key":"819_CR61","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s10787-021-00879-8","volume":"29","author":"A Arora","year":"2021","unstructured":"Arora A, Behl T, Sehgal A et al (2021) Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus. Inflammopharmacology 29(6):1625\u20131639","journal-title":"Inflammopharmacology"},{"key":"819_CR62","doi-asserted-by":"publisher","unstructured":"Yoon J, Lee DG, Song H et al (2024) Xelaglifam, a novel GPR40\/FFAR1 agonist, exhibits enhanced \u03b2-arrestin recruitment and sustained glycemic control for type 2 diabetes. Biomed Pharmacother 177. https:\/\/doi.org\/10.1016\/j.biopha.2024.117044","DOI":"10.1016\/j.biopha.2024.117044"},{"issue":"8","key":"819_CR63","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/13543784.2016.1189530","volume":"25","author":"Z Li","year":"2016","unstructured":"Li Z, Qiu Q, Geng X et al (2016) Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development. Expert Opin Investig Drugs 25(8):871\u2013890. https:\/\/doi.org\/10.1080\/13543784.2016.1189530","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"819_CR64","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1017\/S0954422410000089","volume":"23","author":"Sleeth","year":"2010","unstructured":"Sleeth ML, Thompson EL, Ford HE et al (2010) Free fatty acid receptor 2 and nutrient sensing: a proposed role for fibre, fermentable carbohydrates and short-chain fatty acids in appetite regulation. Nutr Res Rev 23(1):135\u2013145. https:\/\/doi.org\/10.1017\/S0954422410000089","journal-title":"Nutr Res Rev"},{"key":"819_CR65","doi-asserted-by":"publisher","unstructured":"Karaki SI, Mitsui R, Hayashi H et al (2006) Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. Cell Tissue Res 324:353\u2009\u2013\u200960. https:\/\/doi.org\/10.1007\/s00441-005-0140-x","DOI":"10.1007\/s00441-005-0140-x"},{"key":"819_CR66","doi-asserted-by":"publisher","unstructured":"Tolhurst G, Heffron H, Lam YS et al (2012) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein\u2013coupled receptor FFAR2. Diabetes 61(2):364\u2009\u2013\u200971. https:\/\/doi.org\/10.2337\/db11-1019","DOI":"10.2337\/db11-1019"},{"key":"819_CR67","doi-asserted-by":"publisher","unstructured":"Villa SR, Priyadarshini M, Fuller MH et al (2016) Loss of free fatty acid receptor 2 leads to impaired islet mass and beta cell survival. Sci Rep 6:28159 . https:\/\/doi.org\/10.1038\/srep28159","DOI":"10.1038\/srep28159"},{"key":"819_CR68","doi-asserted-by":"publisher","unstructured":"Persson SM, Casselbrant A, Alarai A et al (2024) Role of FFAR3 in ketone body regulated glucagon-like peptide 1 secretion. Biochemistry and Biophys Rep 39. https:\/\/doi.org\/10.1016\/j.bbrep.2024.101749","DOI":"10.1016\/j.bbrep.2024.101749"},{"key":"819_CR69","unstructured":"Latif W, Lambrinos KJ, Patel P et al (2021) Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs). PMID: 34283517"},{"key":"819_CR70","doi-asserted-by":"publisher","unstructured":"Zhang Y, Sun B, Feng D et al (2017) Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature 546(7657):248\u201353. https:\/\/doi.org\/10.1038\/nature22394","DOI":"10.1038\/nature22394"},{"issue":"12","key":"819_CR71","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/s41422-020-0384-8","volume":"30","author":"H Ma","year":"2020","unstructured":"Ma H, Huang W, Wang X et al (2020) Structural insights into the activation of GLP-1R by a small molecule agonist. Cell Res 30(12):1140\u20131142. https:\/\/doi.org\/10.1038\/s41422-020-0384-8","journal-title":"Cell Res"},{"key":"819_CR72","doi-asserted-by":"publisher","unstructured":"Bitsi S, El Eid L, Manchanda Y et al (2023) Divergent acute versus prolonged pharmacological GLP-1R responses in adult \u03b2 cell\u2013specific \u03b2-arrestin 2 knockout mice. Sci Adv 9(18). https:\/\/doi.org\/10.1126\/sciadv.adf7737","DOI":"10.1126\/sciadv.adf7737"},{"issue":"7","key":"819_CR73","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1210\/me.2015-1007","volume":"29","author":"M Priyadarshini","year":"2015","unstructured":"Priyadarshini M, Villa SR, Fuller M et al (2015) An acetate-specific GPCR, FFAR2, regulates insulin secretion. Mol Endocrinol 29(7):1055\u20131066. https:\/\/doi.org\/10.1210\/me.2015-1007","journal-title":"Mol Endocrinol"},{"issue":"3","key":"819_CR74","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/MJT.0b013e3181c08081","volume":"17","author":"V Bermudez","year":"2010","unstructured":"Bermudez V, Finol F, Parra N et al (2010) PPAR-\u03b3 agonists and their role in type 2 diabetes mellitus management. Am J Ther 17(3):274\u2013283. https:\/\/doi.org\/10.1097\/MJT.0b013e3181c08081","journal-title":"Am J Ther"},{"key":"819_CR75","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41392-025-02270-3","volume":"10","author":"P Jin","year":"2025","unstructured":"Jin P, Duan X, Huang Z et al (2025) Nuclear receptors in health and disease: signaling pathways, biological functions and pharmaceutical interventions. Signal Transduct Target Ther 10:228. https:\/\/doi.org\/10.1038\/s41392-025-02270-3","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"819_CR76","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.3390\/ijms23095025","volume":"23","author":"M V\u00e1zquez-Carrera","year":"2022","unstructured":"V\u00e1zquez-Carrera M, Wahli W (2022) PPARs as key mediators in the regulation of metabolism and inflammation. Int J Mol Sci 23(9):5025. https:\/\/doi.org\/10.3390\/ijms23095025","journal-title":"Int J Mol Sci"},{"issue":"3","key":"819_CR77","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1002\/mco2.283","volume":"4","author":"R Cao","year":"2023","unstructured":"Cao R, Tian H, Zhang Y et al (2023) Signaling pathways and intervention for therapy of type 2 diabetes mellitus. MedComm 4(3):e283. https:\/\/doi.org\/10.1002\/mco2.283","journal-title":"MedComm"},{"issue":"6","key":"819_CR78","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2174\/0115733998254798231005095627","volume":"20","author":"G Singh","year":"2024","unstructured":"Singh G, Kumar R, DS D et al (2024) Thiazolidinedione as a promising medicinal scaffold for the treatment of type 2 diabetes. Curr Diabetes Rev 20(6):89\u2013109. https:\/\/doi.org\/10.2174\/0115733998254798231005095627","journal-title":"Curr Diabetes Rev"},{"issue":"4","key":"819_CR79","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/03602532.2025.2508152","volume":"57","author":"A Jangra","year":"2025","unstructured":"Jangra A, Babu B, Divakar S et al (2025) An in-depth review of PPAR\u03b3 modulators as anti-diabetes therapeutics. Drug Metab Rev 57(4):311\u2013337. https:\/\/doi.org\/10.1080\/03602532.2025.2508152","journal-title":"Drug Metab Rev"},{"issue":"5","key":"819_CR80","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jmb.2009.01.025","volume":"386","author":"A Motani","year":"2009","unstructured":"Motani A, Wang Z, Weiszmann J et al (2009) INT131: a selective modulator of PPAR\u03b3. J Mol Biol 386(5):1301\u20131311. https:\/\/doi.org\/10.1016\/j.jmb.2009.01.025","journal-title":"J Mol Biol"},{"key":"819_CR81","doi-asserted-by":"publisher","unstructured":"Chandalia A, Clarke HJ, Clemens LE et al (2009) MBX-102\/JNJ39659100, a novel non\u2010TZD selective partial PPAR\u2010\u03b3 agonist lowers triglyceride independently of PPAR\u2010\u03b1 activation. PPAR Res 2009:706852. https:\/\/doi.org\/10.1155\/2009\/706852","DOI":"10.1155\/2009\/706852"},{"issue":"3","key":"819_CR82","doi-asserted-by":"publisher","first-page":"104318","DOI":"10.1016\/j.drudis.2025.104318","volume":"30","author":"Z Xie","year":"2025","unstructured":"Xie Z, Xin J, Huang C et al (2025) Drugs targeting peroxisome proliferator-activated receptors. Drug Discov Today 30(3):104318. https:\/\/doi.org\/10.1016\/j.drudis.2025.104318","journal-title":"Drug Discov Today"},{"key":"819_CR83","doi-asserted-by":"publisher","first-page":"146281","DOI":"10.1016\/j.molstruc.2026.146281","volume":"1368","author":"P Arora","year":"2026","unstructured":"Arora P, Tyagi A, Kumar V et al (2026) Emerging Multi-Target Strategies and Dual Agonists of PPAR-\u03b1\/\u03b3 Modulation in Type 2 Diabetes. J Mol Struct 1368:146281. https:\/\/doi.org\/10.1016\/j.molstruc.2026.146281","journal-title":"J Mol Struct"},{"key":"819_CR84","doi-asserted-by":"publisher","first-page":"170213","DOI":"10.1016\/j.peptides.2019.170213","volume":"125","author":"K El","year":"2020","unstructured":"El K, Campbell JE (2020) The role of GIP in \u03b1-cells and glucagon secretion. Peptides 125:170213. https:\/\/doi.org\/10.1016\/j.peptides.2019.170213","journal-title":"Peptides"},{"key":"819_CR85","doi-asserted-by":"publisher","first-page":"1095753","DOI":"10.3389\/fendo.2023.1095753","volume":"14","author":"I Zaffina","year":"2023","unstructured":"Zaffina I, Pelle MC, Armentaro G (2023) Effect of dual glucose-dependent insulinotropic peptide\/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity. Front Endocrinol 14:1095753. https:\/\/doi.org\/10.3389\/fendo.2023.1095753","journal-title":"Front Endocrinol"},{"issue":"12","key":"819_CR86","doi-asserted-by":"publisher","first-page":"108332","DOI":"10.1016\/j.jdiacomp.2022.108332","volume":"36","author":"ST Bull","year":"2022","unstructured":"Bull ST, Nuffer W, Trujillo JM (2022) Tirzepatide: A novel, first-in-class, dual GIP\/GLP-1 receptor agonist. J Diabetes Complicat 36(12):108332. https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108332","journal-title":"J Diabetes Complicat"},{"key":"819_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2026.02.006","author":"F Zhang","year":"2026","unstructured":"Zhang F, Chen W, Wang H et al (2026) A novel GIPR\/GLP-1R dual agonist improves systemic metabolism through differentially regulating inflammation and lipid metabolism in obesity. J Adv Res. https:\/\/doi.org\/10.1016\/j.jare.2026.02.006","journal-title":"J Adv Res"},{"issue":"7","key":"819_CR88","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1080\/13543776.2020.1769600","volume":"30","author":"C Cheng","year":"2020","unstructured":"Cheng C, Jabri S, Taoka BM et al (2020) Small molecule glucagon receptor antagonists: an updated patent review (2015\u20132019). Expert Opin Ther Pat 30(7):509\u2013526. https:\/\/doi.org\/10.1080\/13543776.2020.1769600","journal-title":"Expert Opin Ther Pat"},{"key":"819_CR89","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fnagi.2013.00042","volume":"5","author":"W Fu","year":"2013","unstructured":"Fu W, Patel A, Jhamandas JH (2013) Amylin receptor: a common pathophysiological target in Alzheimer\u2019s disease and diabetes mellitus. Front Aging Neurosci 5:42. https:\/\/doi.org\/10.3389\/fnagi.2013.00042","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"819_CR90","doi-asserted-by":"publisher","first-page":"e1480","DOI":"10.1096\/fba.2024-00151","volume":"7","author":"T Muhammad","year":"2025","unstructured":"Muhammad T, Pastore SF, Good K et al (2025) The role of amylin, a gut\u2013brain axis hormone, in metabolic and neurological disorders. FASEB Bioadv 7(3):e1480. https:\/\/doi.org\/10.1096\/fba.2024-00151","journal-title":"FASEB Bioadv"},{"issue":"4","key":"819_CR91","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3390\/molecules28041583","volume":"28","author":"D Eliwa","year":"2023","unstructured":"Eliwa D, Kabbash A, El-Aasr M et al (2023) Papaverinol-N-Oxide: A Microbial Biotransformation Product of Papaverine with Potential Antidiabetic and Antiobesity Activity Unveiled with In Silico Screening. Molec 28(4):1583. https:\/\/doi.org\/10.3390\/molecules28041583","journal-title":"Molec"},{"key":"819_CR92","doi-asserted-by":"publisher","unstructured":"Li C, Yang M, Wang X et al (2018) Glutazumab, a novel long-lasting GLP-1\/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites. Biochem Pharmacol 150:46\u201353. https:\/\/doi.org\/10.1016\/j.bcp.2018.01.029","DOI":"10.1016\/j.bcp.2018.01.029"},{"key":"819_CR93","doi-asserted-by":"publisher","unstructured":"Coskun T, Sloop KW, Loghin C et al (2018) LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 18:3\u201314. https:\/\/doi.org\/10.1016\/j.molmet.2018.09.009","DOI":"10.1016\/j.molmet.2018.09.009"},{"key":"819_CR94","doi-asserted-by":"publisher","unstructured":"Zimmermann T, Thomas L, Baader-Pagler T et al (2022) BI 456906: Discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab 66. https:\/\/doi.org\/10.1016\/j.molmet.2022.101633","DOI":"10.1016\/j.molmet.2022.101633"},{"issue":"10","key":"819_CR95","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.3390\/ijms19103053","volume":"19","author":"Q Wang","year":"2018","unstructured":"Wang Q, Zhao C, Jin L et al (2018) AWRK6, a novel GLP-1 receptor agonist, attenuates diabetes by stimulating insulin secretion. Int J Mol Sci 19(10):3053. https:\/\/doi.org\/10.3390\/ijms19103053","journal-title":"Int J Mol Sci"},{"key":"819_CR96","doi-asserted-by":"publisher","unstructured":"Pan H, Su Y, Xie Y et al (2020) Everestmab, a novel long-acting GLP-1\/anti GLP-1R nanobody fusion protein, exerts potent anti-diabetic effects. Artif Cells Nanomed Biotechnol 48(1):854\u2009\u2013\u200966. https:\/\/doi.org\/10.1080\/21691401.2020.1770268","DOI":"10.1080\/21691401.2020.1770268"},{"key":"819_CR97","doi-asserted-by":"publisher","unstructured":"Bossart M, Wagner M, Elvert R et al (2022) Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1\/GIP\/GCG receptor triagonist. Cell Metab 34(1): P59\u201374. https:\/\/doi.org\/10.1016\/j.cmet.2021.12.005","DOI":"10.1016\/j.cmet.2021.12.005"},{"key":"819_CR98","doi-asserted-by":"publisher","unstructured":"Dong G, Ye Q, Li W (2025) Discovery and evaluation of DA-302168S as an efficacious oral small-molecule glucagon-like peptide-1 receptor agonist. J Med Chem 68: 9555\u201383. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00242","DOI":"10.1021\/acs.jmedchem.5c00242"},{"key":"819_CR99","doi-asserted-by":"publisher","unstructured":"Priyadarshini M, Navarro G, Layden BT (2018) Gut microbiota: FFAR reaching effects on islets. Endocrinology 159(6):2495-505. https:\/\/doi.org\/10.1210\/en.2018-00296","DOI":"10.1210\/en.2018-00296"},{"key":"819_CR100","doi-asserted-by":"publisher","unstructured":"Oteng AB, Liu L (2023) GPCR-mediated effects of fatty acids and bile acids on glucose homeostasis. Front Endocrinol 14:1206063. https:\/\/doi.org\/10.3389\/fendo.2023.1206063","DOI":"10.3389\/fendo.2023.1206063"},{"key":"819_CR101","doi-asserted-by":"publisher","unstructured":"Lee DH, Heo KS, Myung CS (2023). G\u03b1i\u2010coupled GPR41 activation increases Ca2+ influx in C2C12 cells and shows a therapeutic effect in diabetic animals. Obesity 31(7):1871-83. https:\/\/doi.org\/10.1002\/oby.23786","DOI":"10.1002\/oby.23786"},{"key":"819_CR102","doi-asserted-by":"publisher","unstructured":"Saran A, Raisinghani R, Paliwal S et al (2026) GLP-1R agonists: recent advances, current gaps, and future challenges. Mol Divers 30:101-12. https:\/\/doi.org\/10.1007\/s11030-025-11195-6","DOI":"10.1007\/s11030-025-11195-6"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00819-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-026-00819-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00819-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:36:30Z","timestamp":1789410990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-026-00819-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":102,"alternative-id":["819"],"URL":"https:\/\/doi.org\/10.1007\/s42000-026-00819-7","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest, financial or otherwise.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}